Skip to content

Study · Non-randomized trial · n = 22 · 1991

2 results

Oxytocin does not modify the prolactin response to metoclopramide in normal women.

Chiodera P, Volpi R, Gramellini D, Cigarini C, Corradi A, Cavazzini U, Bianconi L, Papadia C, Caiazza A, Capretti L

Journal of endocrinological investigation1 Jun 1991Cited by 1 (Europe PMC)

PMID1774442 (opens in a new tab)DOI10.1007/bf03346844 (opens in a new tab)PepBankPUB-01774442
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In normal women, oxytocin did not modify the prolactin response to either 1 mg or 10 mg metoclopramide.

    In plain wordsIn healthy women, oxytocin did not change the prolactin rise caused by metoclopramide.

    Peptide
    Oxytocin
    Outcome
    No significant changeProlactin response to metoclopramide with oxytocin
    Study

    n = 22

    Comparator
    Metoclopramide without oxytocin
    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    2 IU injected plus 0.033 IU/min infused · 2 hoursAs given in this study (human).

    Source sentences

    Summary
    OT was found unable to modify the effect of either 1 or 10 mg MCP
    2 context sentences
    Summary · context
    The present study was undertaken in order to establish whether oxytocin (OT) affects the dopaminergic control of PRL secretion in normal women during follicular, periovulatory and luteal phase of their menstrual cycle.
    Summary · context
    For this purpose, 22 normal women were tested with a lower (1 mg) or higher (10 mg) dose of the dopaminergic antagonist metoclopramide (MCP) with or without the concurrent treatment with OT (2 IU injected plus 0.033 IU/min infused for 2 h).
  2. 02HumanNon-randomized trialEfficacy outcome

    In normal women given dopamine infusion first, oxytocin again failed to modify the prolactin response to metoclopramide.

    In plain wordsIn healthy women who first received dopamine, oxytocin still did not change the prolactin response to metoclopramide.

    Peptide
    Oxytocin
    Outcome
    No significant changeProlactin response to metoclopramide after dopamine infusion with oxytocin
    Study

    n = 22

    Comparator
    Metoclopramide without oxytocin
    Outcome group
    Pituitary hormones · Endocrine and hormones
    Studied dose
    2 IU injected plus 0.033 IU/min infused · 2 hoursAs given in this study (human).

    Source sentences

    Summary
    Also in these experimental conditions OT failed to modify the PRL response to MCP.
    2 context sentences
    Summary · context
    The present study was undertaken in order to establish whether oxytocin (OT) affects the dopaminergic control of PRL secretion in normal women during follicular, periovulatory and luteal phase of their menstrual cycle.
    Summary · context
    For this purpose, 22 normal women were tested with a lower (1 mg) or higher (10 mg) dose of the dopaminergic antagonist metoclopramide (MCP) with or without the concurrent treatment with OT (2 IU injected plus 0.033 IU/min infused for 2 h).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:52 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.